Zydus Wellness Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges

Quality Assessment: A Mixed Picture Amidst Operational Struggles

Zydus Wellness operates in the FMCG sector, classified as a small-cap company with a Market Capitalisation Grade reflecting its size. Over the past five years, the company’s net sales have grown at a modest annual rate of 14.15%, while operating profit growth has been notably weaker at 3.21%. This sluggish profitability growth has contributed to a Very Negative financial performance in the recent quarter Q3 FY25-26, with operating profit falling sharply by 36.36%.

The company has reported negative results for two consecutive quarters, including the September 2025 quarter, signalling persistent operational challenges. Profit After Tax (PAT) for the nine months ended December 2025 declined by 55.24% to ₹76 crores, while Profit Before Tax excluding other income (PBT less OI) plunged by 147.1% to a loss of ₹35.7 crores. Interest expenses have surged dramatically by 749.25% over the last six months, reaching ₹56.9 crores, indicating increased financial strain.

Despite these setbacks, Zydus Wellness maintains a strong ability to service its debt, evidenced by an average EBIT to Interest ratio of 14.07. This suggests that while profitability is under pressure, the company’s operational earnings remain sufficient to cover interest obligations comfortably.

Valuation: Attractive Metrics Amidst Profitability Concerns

From a valuation standpoint, Zydus Wellness presents an attractive profile. The company’s Return on Capital Employed (ROCE) stands at a modest 3.8%, but it benefits from a low Enterprise Value to Capital Employed ratio of 1.9, indicating that the stock is trading at a fair value relative to its capital base. This valuation is in line with historical averages for its peer group within the FMCG sector.

While the stock’s profitability has declined by 22.6% over the past year, its market performance has been robust. The share price has delivered a 33.55% return over the last 12 months, significantly outperforming the BSE500 index’s 5.94% gain. This divergence between earnings and price performance suggests that investors may be pricing in a recovery or valuing the company on other factors such as brand strength or market positioning.

Financial Trend: Negative Earnings but Mixed Returns

The financial trend for Zydus Wellness remains challenging. The company’s quarterly results have been disappointing, with two consecutive quarters of negative earnings and a steep decline in operating profit. The nine-month PAT contraction of 55.24% and the significant increase in interest costs highlight the pressures on profitability and cash flow.

However, the stock’s return profile over various time horizons paints a more nuanced picture. While the year-to-date return is negative at -7.10%, the one-year return is a strong 33.55%, and the three-year return stands at 44.13%, both outperforming the Sensex’s respective returns of 2.27% and 31.00%. Over a decade, the stock’s return of 201.97% closely matches the Sensex’s 205.90%, indicating long-term value creation despite recent setbacks.

Institutional investors hold a significant 21.85% stake in the company, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing may provide some stability amid the current financial headwinds.

Technicals: Key Driver Behind Upgrade to Sell

The primary catalyst for the upgrade from Strong Sell to Sell is the improvement in technical indicators. The technical grade has shifted from bearish to mildly bearish, signalling a potential stabilisation in the stock’s price trend. Key technical metrics reveal a mixed but improving outlook:

• MACD (Moving Average Convergence Divergence) is bearish on the weekly chart but mildly bearish on the monthly chart, suggesting short-term weakness but longer-term stabilisation.
• RSI (Relative Strength Index) shows no clear signal on both weekly and monthly timeframes, indicating neither overbought nor oversold conditions.
• Bollinger Bands indicate sideways movement on the weekly chart and a bullish trend on the monthly chart, reflecting reduced volatility and a possible upward momentum.
• Moving averages on the daily chart remain mildly bearish, but the KST (Know Sure Thing) indicator is bearish weekly and bullish monthly, further supporting a cautiously optimistic technical outlook.
• Dow Theory analysis shows no clear trend weekly and mildly bearish monthly, while On-Balance Volume (OBV) indicates no trend on either timeframe.

These technical signals collectively suggest that while the stock is not yet in a strong uptrend, the worst of the bearish momentum may be abating. This technical improvement has prompted the MarketsMOJO rating to upgrade the stock’s Mojo Grade from Strong Sell to Sell, with a current Mojo Score of 31.0.

Price and Market Performance Context

On 17 March 2026, Zydus Wellness’s stock closed at ₹424.05, up 5.00% from the previous close of ₹403.85. The day’s trading range was ₹405.00 to ₹438.30, with the 52-week high at ₹530.55 and the low at ₹311.06. This price action reflects renewed investor interest and aligns with the technical indicators signalling a potential bottoming out.

Comparatively, the stock has outperformed the Sensex and broader market indices over the medium to long term, despite recent earnings disappointments. This divergence underscores the importance of considering multiple factors when assessing investment potential.

Conclusion: Balanced Outlook with Technical Optimism

Zydus Wellness Ltd’s upgrade from Strong Sell to Sell reflects a cautious optimism driven by technical improvements amid ongoing financial challenges. The company’s operational performance remains under pressure, with declining profits and rising interest costs dampening the fundamental outlook. However, attractive valuation metrics, strong institutional ownership, and a history of market-beating returns provide some counterbalance.

Investors should weigh the company’s weak recent financial trends against the improving technical signals that suggest a potential stabilisation in share price. The current Mojo Score of 31.0 and Sell rating indicate that while the stock is not yet a buy, it may be approaching a level where downside risks are moderating.

Careful monitoring of upcoming quarterly results and technical developments will be essential for investors considering exposure to Zydus Wellness. The stock’s performance relative to sector peers and broader market indices will also be critical in assessing its future trajectory.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →